|
|
Post by Hot Christian Stocks on Feb 10, 2014 9:20:43 GMT -5
$PLPL Completes $15.3 Million Funding Commitment NEW YORK, NY- via eTeligis (Feb 10, 2014) - Planda Biotechnology, Inc. (OTCQB:PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, announced today that it has entered into a stock purchase agreement with Lincoln Park Capital Fund, LLC, a Chicago-based institutional investor, whereby Lincoln Park committed to invest, at the Company's sole option, up to $15.3 million of equity capital over the term of the purchase agreement including an initial investment of $300,000. Roger Duffield, Chief Executive Officer of Planda, commented on the agreement, "This agreement with Lincoln Park gives Planda the flexibility to access capital over the next few years at prevailing market prices and as the need arises.As we enter into production and commence sales in the coming months, it is important to have a strong balance sheet and the ability to continue our research in green tea, citrus and to brand our cannabis extracts under the Diego Pellicer Gold label." During the 30-month term of the stock purchase agreement the Company, at its sole discretion, has the right to sell to Lincoln Park up to an additional $15 million of its common stock, in amounts as described in the agreement and subject to certain conditions, which include the effectiveness of a registration statement with the U.S. Securities and Exchange Commission covering the sale of the shares that may be issued to Lincoln Park.The Company controls the timing and amount of any future investment and Lincoln Park is obligated to make purchases, if and when the Company decides, in accordance with the purchase agreement. There are no upper limits to the price Lincoln Park may pay to purchase Planda common stock and the purchase price of the shares related to any future investments will be based on the prevailing market prices of the Company's shares immediately preceding the notice of sale to Lincoln Park.Lincoln Park has agreed not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of the Company's shares of common stock.The agreement may be terminated by the Company at any time, at its sole discretion, without any monetary cost.The proceeds from this investment will be used for research, product development, marketing and general operating purposes. A more detailed description of the agreement is set forth in the Company's Current Report on Form 8-K recently filed with the SEC which the Company encourages be reviewed carefully. www.stockwatch.com/News/Item.aspx?bid=U-et1014843506-U%3aPLPL-20140210&symbol=PLPL®ion=U |
|
|
|
Post by Hot Christian Stocks on Feb 11, 2014 8:25:24 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Feb 12, 2014 9:23:29 GMT -5
$PLPL some nice dd -Plandai Biotechnology Offers Significant Growth Potential seekingalpha.com/article/2012401-plandai-biotechnology-offers-significant-growth-potential Although the stock market has gotten off to a shaky start in 2014, there are still plenty of new investing opportunities. One company that has been a shining star thus far in 2014 is Plandai Biotechnology(OTCQB:PLPL). Investors looking for a small-cap company capable of participating in a fast-growing market that is riding a paradigm shift in government regulations should strongly consider Plandai Biotechnology. Company ProfileThe company develops highly bioavaiable, phytonutrient rich extracts that are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai controls every aspect of the process, from growing the raw materials on its farms in South Africa to producing its patented Phytofare extracts-in-house, allowing the company to guarantee the continuity of supply as well as control throughout the entire process. Entry into CannabisHowever, one of the primary reasons why Plandai Biotechnology stood out as a potential winning investment is because of the company's recent decision to form a new division called Cannabis Biosciences. The company announced on November 1, 2013, that it planned to create a new wholly-owned subsidiary to develop and test a new Phytofare botanical extract derived from cannabis. Given that the Plandai team already has specific and unique knowledge related to bioavailability and extraction capabilities, this is likely a wise decision as the company should have significant competitive advantages over its peers in the industry who simply want to ride the waves of the medical marijuana revolution. Following a series of studies and trials, Plandai's offerings have demonstrated the highest bioavailability in the industry. In somestatistics, the absorption rate into the bloodstream was more than 8 times that of competing products. Moreover, competing products and approaches do not have the validation that Plandai has received via the recently formed relationship with Diego Pellicer. It is clear that the number one brand in the cannabis industry would seek out a partnership with the company that has produced the greatest bioavailability. |
|
|
|
Post by Hot Christian Stocks on Feb 13, 2014 9:57:37 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Feb 13, 2014 11:29:09 GMT -5
$PLPL Names Jamen Shively, co-founder of the Diego Pellicer to its Board of Directors NEW YORK, NY--(Marketwired - Feb 13, 2014) - Plandaí Biotechnology, Inc. (OTCQB: PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, announced today that it has named Jamen Shively, a leading voice in the burgeoning marijuana industry and co-founder of the Diego Pellicer group of companies, to its Board of Directors. Mr. Shively will be filling the vacancy created with the resignation of David Rzepnicki, who recently resigned. Roger Duffield, Chief Executive Officer of Plandaí, commented on the appointment of Mr. Shively to the Board, "Jamen brings a wealth of experience in both engineering and branding to Plandaí not to mention his bold leadership in the cannabis field. As a member of Plandaí's Board, Jamen will be instrumental in helping shape our corporate policy and direction as we move from being a research company into production and sales in the coming months." Jamen Shively, age 45, has a background in engineering and marketing, with specialties in artificial intelligence, the modeling and optimization of complex networks, and the creation and positioning of new categories of products and services. Jamen co-founded Diego Pellicer Inc. in 2012, and built the brand from zero to the #1 most recognized brand of cannabis in the world in less than one year. Prior to founding Diego Pellicer, Jamen worked for Microsoft from 2003 to 2009 as Corporate Strategy Manager, where he focused on the creation and development of new categories of software products and online services. Preceding his Microsoft career he headed Shively International Inc., which built and operated both cybercafés and educational computer centers in Mexico. Just prior to founding Diego Pellicer Inc., Jamen founded and headed the online marketplace for the specialty food industry, Findood, winning first place in the Northwest Entrepreneur Network's First Look Forum Competition for the top new startup in 2010. Jamen completed his undergraduate work at U.C. Berkeley in Civil Engineering, and did graduate work at M.I.T. and U.C. Berkeley in Civil Engineering and Materials Science. He is a Fellow of the National Science Foundation. Mr. Duffield added, "We are grateful for the years of service Mr. Rzepnicki provided to myself and to Plandaí over the past decade. He was one of the first to grasp the vision of the company and has been an unflagging ally over the years. As he focuses on his family and other business opportunities, we extend our sincerest thanks." finance.yahoo.com/news/plandai-biotechnology-names-diego-pellicer-160500298.html |
|
|
|
Post by Hot Christian Stocks on Feb 14, 2014 9:04:42 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Feb 18, 2014 9:47:42 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Feb 19, 2014 9:24:09 GMT -5
$PLPL Recent Marijuana News From Washington, D.C., Pivotal to Plandai Biotechnology's Success in the Industry NEW YORK, NY -- (Marketwired) -- 02/19/14 Plandaí Biotechnology (OTCQB: PLPL) executives are certainly in favor of what 18 legislators are trying to accomplish with their letter to President Obama asking him to reclassify marijuana. They're likely equally as elated with news from the Administration last Friday that paves the way for legal banking between legitimate marijuana businesses and U.S. banks. Things are moving very fast in the marijuana debate, and with each news event, there appears to be a real acceptance of the drug's future in this country. Last week's announcements certainly favor Plandaí's future in an industry that continues to be shaped by events. The guidance issued by the Justice and Treasury departments is the latest step by the federal government toward enabling a legalized marijuana industry to operate in states that approve it. The intent is to make banks feel more comfortable working with marijuana businesses that are licensed and regulated. This guidance will directly affect Plandaí at some point in the future as it works with Diego Pellicer to brand its Phytofare cannabis extracts. If successful, the letter sent to President Obama from 18 members of congress, will also directly affect Plandaí and its ability to use marijuana legally in its extracts and its research. Legislators are asking Obama to use his authority to reclassify marijuana by removing it from the Schedule I category. Currently marijuana is viewed in the same category as heroin and LSD, and these 18 legislators say this status "makes no sense." The letter read, "We request that you instruct Attorney General Holder to delist or classify marijuana in a more appropriate way, at the very least eliminating it from Schedule I or II." It went on to state: "Classifying marijuana as Schedule I at the federal level perpetuates an unjust and irrational system. Schedule I recognizes no medical use, disregarding both medical evidence and the laws of nearly half of the states that have legalized medical marijuana." www.stockwatch.com/News/Item.aspx?bid=U-i1091080-U%3aPLPL-20140219&symbol=PLPL®ion=U |
|
|
|
Post by Hot Christian Stocks on Feb 20, 2014 9:20:12 GMT -5
$PLPL Plandai Biotechnology Names Diego Pellicer Co-Founder and Cannabis Pioneer Jamen Shively as Vice President of Global MarketingNEW YORK, NY- via eTeligis (Feb 20, 2014) - Planda Biotechnology, Inc. (OTCQB:PLPL), a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, announced today that Jamen Shively, a leading voice in the burgeoning marijuana industry and recently appointed Board Member of Planda, has been named as Vice President of Global Marketing. As VP-Global Marketing, the company released, Mr. Shively will be responsible for building brand awareness and marketing strategy for all of Planda's operations including the Diego Pellicer(R) medical cannabis line as well as the Phytofare botanical extracts such as the Green Tea Catechin Complex and the Limonoid Glycoside Complex. Roger Duffield, Chief Executive Officer of Planda, commented on Mr. Shively's new position within the Company, "We're excited to bring Jamen fully into the Planda fold.He did a brilliant job building the Diego Pellicer brand, and we're confident that he will build on this experience as we launch the first of our products in the coming weeks.Our goal is to become the leading name in highly bioavailable botanical extracts for both nutraceutical and pharmaceutical applications.Jamen has the vision and expertise to help further us towards that end." Mr. Shively stated, "I could not be more pleased to come aboard Planda, first as a Director and now as a full-time member of the management team.Planda is uniquely positioned in that it has no real direct competition -- no one else in the market is selling high bioavailability plant extracts. Consumers are starting to demand more from their vitamins and supplements and asking to what extent are the billions of dollars being spent on such products actually increasing health and wellness.My role with Planda, as I see it, is to educate the consumer that they need to demand more from their supplements while also telling the Planda story.We have a unique opportunity with Planda's technology to fundamentally change how we address wellness, health and prevention through natural, botanical solutions." He added, "I am also extremely excited about the application of Planda's technologies to cannabis, which I believe will revolutionize the application of cannabis to preventive and therapeutic health, under the Diego Pellicer brand.This is the opportunity of a lifetime for me and for my colleagues at Plandai to change the world by improving the health and wellness of mankind through 100% natural plant extracts.We are unlocking the potential of nature's plant nutrients for humans and animals alike." Jamen Shively, age 45, has a background in engineering and marketing, with specialties in artificial intelligence, the modeling and optimization of complex networks, and the creation and positioning of new categories of products and services. Jamen co-founded Diego Pellicer Inc. in 2012 and built the brand from zero to the #1 most recognized brand of cannabis in the world in less than one year.Prior to founding Diego Pellicer, Jamen was a Corporate Stategy Manager for Microsoftfrom 2003 to 2009, where he focused on the creation and development of new categories of software products and online services. Preceding his Microsoft career he headed Shively International Inc., which built and operated both cybercafs and educational computer centers in Mexico.Just prior to founding Diego Pellicer Inc., Jamen founded and headed the online marketplace for the specialty food industry, Findood, winning first place in the Northwest Entrepreneur Network's First Look Forum Competition for the top new startup in 2010.Jamen completed his undergraduate work at U.C. Berkeley in Civil Engineering, and did graduate work at M.I.T. and U.C. Berkeley in Civil Engineering and Materials Science. He is a Fellow of the National Science Foundation. www.stockwatch.com/News/Item.aspx?bid=U-et416454128-U%3aPLPL-20140220&symbol=PLPL®ion=U
|
|
|
|
Post by Hot Christian Stocks on Feb 21, 2014 10:34:21 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Feb 25, 2014 9:19:25 GMT -5
$PLPL - Future of Plandai Biotechnology's Products in Good Hands With Former Microsoft Executive Heading Up Global Marketing NEW YORK, NY -- (Marketwired) -- 02/25/14 Today Plandaí Biotechnology (OTCQB: PLPL) named former Microsoft executive Jamen Shively as the company's Vice President of Global Marketing. Shively has an extensive and impressive resume in the world of business, and the company is confident he can deliver Plandaí's products on the world stage. According to Plandaí, Shively will be responsible for building brand awareness and marketing strategy for all of the company's operations. Needless to say, they found just the right man for the future of their products. Since leaving Microsoft, Shively has become a marijuana entrepreneur who has the ability to command the media's attention. So, having Shively build brand awareness for the company's products, including, the Diego Pellicer® medical cannabis line as well as the Phytofare botanical extracts such as the Green Tea Catechin Complex and the Limonoid Glycoside Complex is a brilliant move by Plandaí executives. Shively co-founded Diego Pellicer Inc. in 2012, and then built the brand into the most recognized brand of cannabis in the world in less than one year. Prior to founding Diego Pellicer, Jamen was a Corporate Strategy Manager for Microsoft from 2003 to 2009, where he focused on the creation and development of new categories of software products and online services. Plandaí's CEO stated it is their goal to become the leading name in highly bioavailable botanical extracts for both nutraceutical and pharmaceutical applications. Jamen Shively is someone who can make that a reality, and he sounds more than ready to get started. "We have a unique opportunity with Plandaí's technology to fundamentally change how we address wellness, health and prevention through natural, botanical solutions." Shively said he's also excited about the application of Plandaí's technologies to cannabis. He stated, "I believe they'll revolutionize the application of cannabis to preventive and therapeutic health, under the Diego Pellicer brand. This is the opportunity of a lifetime for me and for my colleagues at Plandai to change the world by improving the health and wellness of mankind through 100% natural plant extracts." Shively's deep interest in the marijuana arena will serve Plandaí well, and his expertise will likely make the company a leading name in highly bioavailable botanical extracts just as the CEO expects. www.stockwatch.com/News/Item.aspx?bid=U-i1091739-U%3aPLPL-20140225&symbol=PLPL®ion=U |
|
|
|
Post by Hot Christian Stocks on Feb 26, 2014 8:43:49 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Feb 27, 2014 9:34:09 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Feb 28, 2014 9:31:50 GMT -5
$PLPL Plandaí subsidiary, Cannabis Biosciences, Inc., will be developing and testing a botanical extract derived from cannabis, and the company its marijuana research will address neural disorders with. Specifically, the company believes that the phytonutrients in cannabis show excellent potential for treating and preventing a host of neuron and injury related brain diseases including Parkinson's, Alzheimer's, ALS, MS, epilepsy, PTSD and post-concussion syndrome www.stockwatch.com/News/Item.aspx?bid=U-by410935-U%3aPLPL-20140114&symbol=PLPL®ion=U |
|
|
|
Post by Hot Christian Stocks on Mar 3, 2014 9:32:21 GMT -5
$PLPL - Plandai Biotechnology: A Natural Fit Into the Marijuana Industry NEW YORK, NY -- (Marketwired) -- 03/03/14 Plandaí Biotechnology (OTCQB: PLPL) has a strong executive team in place, a well thought out business plan, and now it's time for the company to make its products the star. These products include Plandaí's Phytofare botanical extracts such as its Green Tea Catechin Complex and the Limonoid Glycoside Complex, as well as a line of Diego Pellicer® medical cannabis products. It is the latter could make the company a leader in the marijuana industry. Plandaí entered the marijuana space in November 2013, and since that time, the biotech has moved quickly to develop its Phytofare cannabis extracts, it has also found a branding partner in Diego Pellicer, Inc., and it named former Microsoft executive Jamen Shively as the company's Vice President of Global Marketing to build and market the brand of cannabis extracts. None of this should be a surprise however, as Plandaí very well could be the most natural fit of any publicly traded company into the marijuana arena. After all, Plandaí is a producer of highly bioavailable plant extracts for the health, wellness, nutraceutical, and pharmaceutical industries, so adding an additional plant (cannabis) for development into the lineup of botanicals the company already works with (green tea, limonoids) only enhances its product offerings. But, it doesn't stop there. What sets Plandaí apart from many other companies working with botanicals is its hydrodynamic extraction process that allows the company to use science to achieve the most bioavailability from those plants. While tetrahydrocannabinol (THC) has demonstrated the ability to reduce tumors and slow the progression of Alzheimer's, it is the second largest constituent of cannabis, cannabidiol (CBD), which doesn't have psychoactive properties that will likely be the primary focus of Plandaí's testing. A number of recent studies that show the healing and treatment benefits of cannabinoids in diseases like diabetes, ALS, Crohn's disease, multiple sclerosis, among others favor a biotech company like Plandaí that will engage in its own studies using cannabis. www.stockwatch.com/News/Item.aspx?bid=U-i1094447-U%3aPLPL-20140303&symbol=PLPL®ion=U |
|
